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doi:10.1016/j.anndiagpatients usually diagnosed at advanced stages. The aim of this study was to analyze the
clinicopathologic and immunohistochemical characteristics of 12 cases of primary nasal melanomas
in Brazil. Twelve cases of primary nasal melanoma were analyzed histologically and by
immunohistochemistry using the antibodies S-100 protein, HMB-45, Melan-A, CD63 (NKI/C3),
CD68/KP1, fatty acid synthase (FASN), and Ki-67. The mean age of the patients was 60 years, and 7
of 12 patients were men. Microscopically, 10 cases presented level III of invasion; 4 were
amelanotic; and in 7, cells were epithelioid. S-100 protein and FASN were positive in all cases,
whereas 9, 8, 7, and 6 cases were positive for HMB-45, Melan-A, CD63 (NKI/C3), and CD68/KP1,
respectively. Ki-67 labeling index ranged from 11.45% to 28.5% of positive cells. S-100 protein is
more frequently expressed in nasal melanomas than in HMB-45, Melan-A, CD63 (NKI/C3), and
CD68/KP1. FASN seems to be involved in the pathogenesis of nasal melanomas, and also, it can be
helpful to confirm the diagnosis.
© 2012 Elsevier Inc. Open access under the Elsevier OA license. Keywords: Nasal melanoma; Histopathology; Immunohistochemistry; Diagnosis1. Introduction
Mucosal melanomas of the head and neck are rare,
comprising 0.8% to 1.3% of all melanomas [1]. It occurs
most frequently in the nasal cavity of elderly men,
commonly involving the anterior portion of the nasal septum
(33%) and the lateral nasal wall (28%) [2,3]. Patients with
nasal melanomas usually present with epistaxis and nasal
obstruction as well as unilateral polyposis with or without
pigmentation [4]. The etiopathogenesis of this form of
melanoma is poorly understood, and a role of inhaled
carcinogens has been suggested [5].
As in other types of melanomas, the histopathology of





Open access under the Elsevier OA license. by epithelioid, spindle, and plasmacytoid cells arranged in a
sheetlike, organoid, alveolar, solid, or desmoplastic config-
uration [6]. When the individual tumor cells are found to be
melanin rich, the diagnosis is usually not difficult; however,
amelanotic lesions may resemble other benign and malignant
neoplasias, and immunohistochemistry can be helpful to
confirm the diagnosis [3].
The objectives of this study are to analyze the
clinicopathologic characteristics and immunohistochemical
expression of S-100 protein, HMB-45, Melan-A, CD63
(NKI/C3), CD68/KP1, fatty acid synthase (FASN), and Ki-
67 in 12 cases of primary nasal melanoma in Brazil and to
compare them with previous reports in other population.2. Materials and methods
Formalin-fixed, paraffin-embedded tissue blocks were
obtained from 12 patients with primary nasal melanoma.
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and histologic characteristics, excluding the presence of
melanoma at other anatomical sites and, consequently, the
possibility of nasal metastasis. The parameters evaluated
included presence or absence of melanin in the tumor
(melanotic or amelanotic), level of tumor cells invasion,
cellular morphology (epithelioid, spindle, plasmacytoid, or
mixed) and pattern (solid, alveolar, organoid, or pagetoid),
necrosis, and perineural and perivascular invasion.
Cellular invasion was considered according to Prasad et al
[7] as noninvasive (in situ), microinvasive (level I, cell
clusters in the superficial lamina propria), invasive (level II,
cell invasion into the lamina propria), and deep invasive
(level III, invasion into skeletal muscle, bone or cartilage).
For immunohistochemical staining, 3-μm thick sections
mounted on silane-coated glass slides were used. Briefly,
the sections were deparaffinized and rehydrated in graded
ethanol solutions, and after antigen retrieval with EDTA/
Tris buffer (pH 9.0) in a microwave oven (1380 W;
Panasonic, São Paulo, Brazil), endogenous peroxidase
activity was blocked with 20% H2O2 by 5 cycles of 5
minutes each. Overnight incubation with the primary
antibodies (Table 1) diluted in bovine serum albumin was
followed by the secondary antibody conjugated with
polymer dextran marked with peroxidase (Dako EnVision
Labelled Polymer; Dako, Glostrup, Denmark). The
reaction was developed with Permanent Red (Permanent
Red, Liquid Chromogen; Dako) for the primary anti-
bodies S-100 protein, HMB-45, Melan-A, FASN, CD63
(NKI/C3), and CD68/KP1, and diaminobenzidine hydro-
chloride (Sigma, St Louis, Mo) was used as chromogen
for Ki-67. The preparations were lightly counterstained
with Carazzi hematoxylin, mounted with Aquatex
(MERCK, Darmstadt, Germany), and examined by light
microscope. Positive and negative controls were included
in all reactions.
Analysis of S-100 protein, HMB-45, Melan-A, FASN,
CD63 (NKI/C3), and CD68/KP1 was performed using a
combined scoring system based on both the fraction of
positive tumor cells and the predominant staining intensity in
the tumor according to Innocenzi et al [8]. The fraction ofTable 1
Antibodies used for immunohistochemical evaluation of 12 cases of primary
nasal melanomas
Antibody Clone Dilution Source
S-100 protein Polyclonal 1:10.000 Dakoa
HMB-45 HMB-45 1:200 Dakoa
Melan-A A103 1:800 Dakoa
CD63 NKI/C3 1:100 Novocastrab
CD68 KP1 1:400 Dakoa
FASN AA9-202 1:200 BD Biosciencesc
Ki-67 MIB-1 1:100 Dakoa
a Dako, Dako Corporation, Carpinteria, Calif.
b Novocastra, Newcastle Upon Tyne, UK.
c BD Biosciences, San Diego, Calif.positive cells was estimated using a 4-tiered scale (b10%, 1;
11%-50%, 2; 51%-80%, 3; N80%, 4). The staining intensity
was graded subjectively from 0 to 3 (negative, 0; low
intensity, 1; moderate, 2; and strong, 3).
Ki-67 nuclear immunohistochemical assessment was
represented by the ratio of positive cells in relation to total
cells, calculated with the help of Aperio ImageScope nuclear
algorithm (Aperio ScanScope; Aperio Technologies, Vista,
Calif). Five high-power fields were randomly selected
(original magnification ×200), and 3000 tumor cells per
slide were counted approximately. The labeling index for Ki-
67 in each case of nasal melanoma was expressed as a
percentage of positive tumor cells.3. Results
Patients' ages ranged from 55 to 71 years, and the
median age of the patients was 60 years. There were 7 men
(58.33%) and 5 women (41.67%), and the main prevalence
of primary nasal melanomas were among whites (7 patients
[58.33%]) against nonwhites (25%; 2 black/Afro-Brazilians,
1 Asian). In 2 cases, we could not identify the patients' race
in the records.
Of 12 primary nasal melanomas studied, 8 were melanotic
and 4 were amelanotic. Ten cases (83.33%) showed deep
cellular invasion (level III) when diagnosed, whereas 2 cases
presented level II. No cases were classified as in situ.
Cellular morphology varied, with 7 cases formed by
epithelioid and 1 by spindle cells, whereas the other 4
cases showed a mixed population of epithelioid and
plasmacytoid cells. Most cases showed a predominant
cellular solid pattern (8 cases '66.66%]), with organoid and
alveolar pattern in only 2 cases each. Necrosis, perivascular,
and perineural invasion was found in 6, 3, and 2 cases,
respectively (Fig. 1).
Immunostaining with S-100 protein, HMB-45, Melan-A,
CD68/KP1, and FASN in melanoma cells was cytoplasmic,
but nuclear staining was also noted with S-100 protein. Only
CD63 (NKI/C3) membrane staining was considered posi-
tive. S-100 protein and FASN were expressed in all cases,
showing strong staining intensity in more than 80% of
malignant cells. HMB-45 was expressed in 9 (75%) of 12
cases of nasal melanomas, with 5 cases demonstrating 51%
to 80% of positive cells and the other 4 showing more than
80% of positive cells. Staining intensity was considered
moderate and strong in 4 and 5 cases, respectively. Melan-A
was expressed in 8 of 12 cases, with strong staining intensity
in more than 80% of positive cells. CD68/KP1 had moderate
staining intensity in 51% to 80% of malignant cells in 6 nasal
melanomas cases (50%). Membrane expression with CD63
(NKI/C3) was observed in 7 cases. Four cases demonstrated
51% to 80% of positive cells, and the other 3 showed more
than 80% of positive cells. Staining intensity was considered
moderate and strong in 3 and 4 cases, respectively. Ki-67
Fig. 1. Histopathologic aspects of primary nasal melanoma (hematoxylin and eosin). (A) Nasal melanoma composed of epithelioid neoplastic melanocytes
arranged in an organoid pattern (original magnification ×400). (B) Nasal melanoma showing perineural invasion of fusiform neoplastic melanocytes (original
magnification ×400). (C) Epithelioid and plasmacytoid neoplastic cells arranged in a solid pattern, showing mitosis figures (original magnification ×400). (D)
Perivascular epithelioid neoplastic melanocytes (original magnification ×400).
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11.45% to 28.5% of positive cells (Figs. 2 and 3).4. Discussion
Nasal melanomas are rare tumors compared with their
cutaneous counterpart, with few reported series. The median
age of diagnosis is 60 years, and most studies show a men
predilection [2,3]. The diagnosis is usually delayed by the
nonspecific nature of signs and symptoms [9]. Series of
head and neck mucosal melanomas in Latin America have
been reported [10,11], and to best of our knowledge, there
are no data on clinical, histologic, and immunohistochem-
ical profiles of primary nasal mucosal melanomas in a
Brazilian population.
The clinical features shown in our series are mostly in
accordance with other reports in the literature. The mean age
of incidence in the cases reported herein was 60 years, and
other authors refer an incidence peak between the fifth and
sixth decades of life [2,3]. We found a slight malepredilection for primary nasal melanomas, as there were 7
men and 5 women in our series. This is in agreement with
other reports that refer a slight predilection for men, although
other authors have reported no sex predilection or a slight
women predilection [2,3]. Ethnic background of the patients
reported herein included 7 whites, 2 Afro-Brazilians, and 1
Asian. There are reported racial differences in the incidence
of primary nasal melanomas, with a higher incidence in
India, Africa, Japan, and some North/Central American
countries with high prevalence of Indian population than in
Europe and Australia [1,2].
Different from the skin, there is not a well-established
clinicopathologic classification of nasal melanomas [7].
Classification and staging of cutaneous melanomas using
Breslow and Clark levels cannot be applied to nasal mucosa
tumors due to structural and morphologic differences
between the skin and respiratory mucosa [5]. In fact, nasal
melanomas differ from cutaneous in several aspects
including risk factors as solar radiation, a family history,
and association with atypical nevi, factors applied mainly to
cutaneous melanoma [5,9]. In contrast to cutaneous
Fig. 2. Immunohistochemical expression of S-100 (A), HMB-45 (B), Melan-A (C), and CD63 (NKI/C3) (D) in primary nasal melanoma (EnVision Permanent
red [A-D], original magnification ×200).
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growth phase, nasal melanomas are found predominantly in
the vertical growth phase, infiltrating skeletal muscle,
cartilage, or bone at the time of diagnosis [5,9]. Most cases
in our study when diagnosed showed deep invasion (level
III), similarly to previous reports of head and neck mucosal
melanomas series [7,10].
Presence ofmelanin was observed in 8 of 12 cases, and it is
known that between 50% and 70% of nasal melanomas
contain melanin that can be easily observed in routine hema-
toxylin and eosin preparations [2,12]. Dauer et al [13] studied
60 cases of sinonasal melanoma finding 17 amelanotic
cases (28%), similar to the values found in our study.
Different cell types, showing epithelioid, spindle, and
plasmacytoid morphology, have been described in nasal
melanomas [9]. In our series, epithelioid cells predominated
in most cases, either as a monomorphous or polymorphous
infiltrate, mixed mainly with plasmacytoid cells. The type of
cellular infiltrate seems to have no impact in prediction of
tumor behavior in nasal melanomas. In our series, the solid
pattern predominated; however, as for the cell type, the
histologic pattern also does not seem to influence prognosis
[10,13].Necrosis, perivascular, and perineural invasion was seen
in 6, 3, and 2 cases, respectively. Although not commonly
observed and, therefore, not considered to be an independent
factor in most prognostic models, vascular invasion when
present in cutaneous melanoma appears to be associated with
a worse prognosis, as this is the first step for regional and
distant metastases [14].
It is well known that melanoma has a wide spectrum of
histologic features, which mimic epithelial, hematologic,
mesenchymal, and neural tumors, and when necessary,
immunohistochemistry is the primary tool to establish the
correct diagnosis. S-100 protein, HMB-45, and Melan-A are
currently the 3 most useful immunomarkers to identify
melanocytes and characterize melanomas [15]. Yu et al [16]
studied the expression of melanocytic differentiation
markers in 17 primary sinonasal and oral melanomas. They
showed that HMB-45, S-100 protein, and Melan-A were
positive in 94%, 88%, and 71% of the cases, respectively,
suggesting that both HMB-45 and S-100 protein are good
markers for immunohistochemical diagnosis of primary
sinonasal and oral melanomas. In this study, we found that S-
100 protein was a more sensitive marker than HMB-45 and
Melan-A, although it is well known to be much less specific.
Fig. 3. Immunohistochemical expression of CD63 (NKI/C3) (A), CD68/KP1 (B), FASN (C), and Ki-67 (D) in primary nasal melanoma (EnVision Permanent red
[A-C], original magnification ×400; immunoperoxidase [D], original magnification ×400).
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and oral melanomas, the least sensitive marker was HMB-
45, marking 85% of the cases, whereas S-100 protein and
Melan-A were positive in approximately 95% of the cases. In
cutaneous melanomas, S-100 protein is the most sensitive
marker with expression in approximately 98% of cases, but
again, it is the least specific [14,15].
We observed CD63 (NKI/C3) expression in 7 cases of
primary nasal melanomas. Only a few studies have analyzed
the use of the CD63 (NKI/C3) antibody in assessing benign
and malignant melanocytic lesions [17,18]. CD63 (NKI/C3)
has a sensitivity of 86% to 100% for cutaneous melanoma in
paraffin-embedded sections but a very poor specificity,
staining neurothekeomas, medullary carcinomas of the
thyroid, granular cell, and neuroendocrine tumors [15]. In
addition, it also stains histiocytes; dendritic, mast, and
endothelial cells; eosinophils; and salivary, bronchial, sweat,
pancreas, and prostate glands. The nonspecificity of this
marker has limited its use in melanoma diagnosis, but it is
important to know its positivity in a high proportion of cases
[15,17].
Similarly to CD63 (NKI/C3), some studies have demon-
strated that melanomas may also stain with the macrophagemarker anti-CD68/KP1 [19,20]. In this study, 6 nasal
melanoma cases had moderate staining intensity for CD68/
KP1. Pernick et al [20] evaluated 43 primary and metastatic
melanomas and observed that expression of CD68/KP1 was
diffusely positive in 86% of cases almost as frequently as
traditional melanoma markers, although with weaker
intensity. Facchetti et al [19] also observed CD68/KP1
positivity in 16 of 20 primary cutaneous melanomas and in 6
of 8 metastatic melanomas, indicating that the expression of
CD68/KP1 might be related to tumor progression in
melanocytic cells.
Fatty acid synthase is the key enzyme responsible for
the synthesis of fatty acids, catalyzing the conversion of
acetyl-CoA and malonyl-CoA into long-chain fatty acids
[8,21,22]. Normal cells do not express FASN because they
use fatty acids from dietary lipids, except those that are
lipogenic. Nevertheless, it is abnormally expressed in many
human cancers cells because of their increased energy need
[8]. There are no data on expression of FASN in primary
nasal melanomas, and only 3 reports consider its relevance
in cutaneous or oral melanomas [8,21,22]. We found that
FASN was strongly expressed in all nasal melanomas
studied, similarly to their cutaneous and oral counterparts,
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of malignant melanocytic lesions. In addition, FASN
activation, as in various other cancers, seems to be relevant
for malignant transformation of nasal mucosa melanocytes.
Ki-67 staining is reported as positive in 13% to 30% of
the cells in cutaneous melanomas, although individual cases
can show almost 100% of nuclear positivity [15,23]. In our
study, Ki-67 showed a proliferating index ranging from
11.45% to 28.5% of positive cells. The present study did not
consider treatment and prognosis of nasal melanomas, but it
is well established that treatment is surgical, often associated
with radiation and/or chemotherapy with a poor prognosis,
showing 2 and 5 years survival of 66.7 % and 31.8%,
respectively [24].
In summary, our findings show that primary nasal
melanomas are rare, occurring in adult and elderly patients
usually diagnosed at advanced stages. It is formed by
epithelioid, spindle, plasmacytoid, or a mixture of these cells
arranged in solid, alveolar, and organoid pattern. S-100
protein and FASN are more frequently expressed than HMB-
45, Melan-A, and CD63 (NKI/C3). CD68/KP1 may also
stain malignant melanoma cells, serving as an additional
melanoma marker. These results also indicate that, as in
cutaneous and oral melanomas, FASN probably plays a role
in the development of nasal melanomas.
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